Get the Stockscreener App
0.1419
0.07%
0.000100
After Hours:
.14
-0.0019
-1.34%
Tonix Pharmaceuticals Holding Corp stock is traded at $0.1419, with a volume of 11.49M.
It is up +0.07% in the last 24 hours and up +1.79% over the past month.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
See More
Previous Close:
$0.1418
Open:
$0.14
24h Volume:
11.49M
Relative Volume:
0.38
Market Cap:
$19.57M
Revenue:
-
Net Income/Loss:
$-121.02M
P/E Ratio:
-0.00759
EPS:
-18.6875
Net Cash Flow:
$-114.09M
1W Performance:
-15.54%
1M Performance:
+1.79%
6M Performance:
-97.58%
1Y Performance:
-99.13%
1-Day Range:
$0.1364
$0.1441
1-Week Range:
$0.136
$0.1775
52-Week Range:
$0.118
$22.14
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
26 MAIN STREET, SUITE 101, CHATHAM, NY
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
Tonix Pharma Partners for Vaccine Clinical Trial - Yahoo Finance
Tonix Pharmaceuticals Announces Research Agreement with Kenya Medical Research Institute (KEMRI) to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya - Yahoo Finance
Tonix Pharmaceuticals Holding Corp. Announces Research Agreement with Kenya Medical Research Institute to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya - Marketscreener.com
Tonix Pharmaceuticals (TNXP) Earnings Date and Reports 2024 - MarketBeat
Tonix reports promising mpox vaccine candidate data By Investing.com - Investing.com South Africa
Tonix reports promising mpox vaccine candidate data - Investing.com
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024 - The Manila Times
Tonix Pharmaceuticals CEO Discusses New Drug Application for Fibromyalgia Treatment - Proactive Investors UK
Tonix Pharmaceuticals Holding (LTS:0A4T) PE Ratio (TTM) : At Loss (As of Oct. 29, 2024) - GuruFocus.com
Tonix Pharmaceuticals to Present at BIO-Europe® 2024 - Yahoo Finance
Tonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference - StockTitan
Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe 2024 - Yahoo Finance
TNXPTonix Pharmaceuticals Holding Corp. Latest Stock News & Market Updates - StockTitan
Tonix Pharmaceuticals Holding (FRA:TPM0) Purchase Of Proper - GuruFocus.com
Tonix Pharma gets DoD contract for antiviral development - Investing.com
Tonix Pharma Secures Defense Contract for Antiviral Development - TipRanks
Tonix Pharma gets DoD contract for antiviral development By Investing.com - Investing.com UK
Tonix Pharmaceuticals Receives First Contract Payment from U.S. Department of Defense for Accelerated Development of Broad-Spectrum Antivirals with the Defense Threat Reduction Agency (DTRA) - The Manila Times
Tonix Pharmaceuticals Receives First Contract Payment from U.S. Department of Defense for Accelerated Development of Broad-Spectrum Antivirals with the Defense Threat Reduction Agency - Marketscreener.com
Empery Asset Management LP Acquires Shares in Tonix Pharmaceuticals - Yahoo Finance
Tonix Pharmaceuticals files NDA for fibromyalgia drug - Investing.com
Tonix Pharmaceuticals files NDA for fibromyalgia drug By Investing.com - Investing.com UK
Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA) - Yahoo Finance
Tonix Pharmaceuticals Partners with X-Chem for AI-Driven Antiviral Development - MSN
Tonix and X-Chem collaborate to accelerate broad-spectrum antiviral development - BioWorld Online
Tonix Pharma Enhances Drug Development with AI Partnership - Yahoo Finance
Tonix secures DoD contract for antiviral drug development By Investing.com - Investing.com South Africa
Tonix secures DoD contract for antiviral drug development - Investing.com
Why Tonix Pharmaceuticals (TNXP) Stock Is Moving - Benzinga
Tonix Pharmaceuticals Presents Promising Data on Fibromyalgia Treatment at Global Conference - Proactive Investors USA
Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals - Yahoo Finance
Tonix Pharm stock hits 52-week low at $0.13 amid steep decline By Investing.com - Investing.com South Africa
StockNews.com Initiates Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) - Defense World
Tonix Pharm stock hits 52-week low at $0.13 amid steep decline - Investing.com Australia
The Rush for Non-Addictive Painkillers to Counter the Opioid Crisis Puts Two Companies Close to FDA Decisions - PharmiWeb.com
Tonix Pharmaceuticals Announces Participation in Endpoints Panel at the Long COVID Workshop and RECOVER TLC Workshop Convened by the Foundation for the National Institutes of Health (FNIH) and the National Institute of Allergy and Infectious Disea - Yahoo Finance
What's Going On With Tonix Pharmaceuticals Stock Friday? - MSN
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Quotes, Forecast and News Summary - Benzinga
Tonix secures patent for migraine treatment into 2036 By Investing.com - Investing.com Canada
Tonix Pharma Secures Patent, Bolsters Migraine Treatment Future - TipRanks
Tonix secures patent for migraine treatment into 2036 - Investing.com
Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat Migraines - StockTitan
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Sees Significant Decline in Short Interest - Defense World
Tonix Pharm stock plunges to 52-week low of $0.13 By Investing.com - Investing.com Australia
Tonix Pharm stock plunges to 52-week low of $0.13 - Investing.com
Tonix Pharmaceuticals advances fibromyalgia treatment - Investing.com
Technical analysis of Tonix Pharmaceuticals Holding Corp (TNXP) stock chart patterns - US Post News
Tonix Pharma Highlights TNX-102 SL at Global Pharmaceutics Conference - TipRanks
Balance Sheet Insights: Tonix Pharmaceuticals Holding Corp (TNXP)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Tonix Pharmaceuticals announces data presentations on TNX-102 SL - TipRanks
Tonix Pharmaceuticals advances fibromyalgia treatment By Investing.com - Investing.com UK
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):